Historical comments on tardive dyskinesia: A neurologist's perspective

Journal of Clinical Psychiatry

Volumn 66, Issue 2, 2005, Pages 260-264

  Paulson, George W ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b Medical Heritage Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AWARENESS; HISTORY OF MEDICINE; MEDICAL LITERATURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TARDIVE DYSKINESIA;

EID: 14644392786     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0216     Document Type: Review

References (64)

1. Jeste DV, Wyatt RJ. Understanding and Treating Tardive Dyskinesia. New York, NY: Guilford Press; 1982
2. Wolf ME, Mosnaim AD. Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. Washington, DC: American Psychiatric Press: 1988
3. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992
4. Wolf MA, Yassa R, Llorca PM. Complications extrapyramidales induites par les neuroleptiques: perspectives historiques. Encephale 1993;19:657-661
5. Delay J, Deniker P. Drug-induced extrapyramidal syndromes. In: Vinken PJ, Bruyn G, eds. Handbook of Clinical Neurology, vol. 6: Basal Ganglia. Amsterdam: North Holland; 1968:248-266
6. Faurbye A, Rasch PJ, Petersen PB, et al. Neurological symptoms in pharmacotherapy of psychosis. Acta Psychiatr Scand 1964;40:10-27
7. Dynes JB. Oral dyskinesias: occurrence and treatment. Dis Nerv Syst 1970;31:854-859
8. Evans JH. Persistent oral dyskinesia in treatment with phenothiazine derivatives. Lancet 1965;1:458-460
9. Druckman R, Seelinger D, Thulin B. Chronic involuntary movements induced by phenothiazines. J Nerv Ment Dis 1962;135:69-76
10. Sigwald J, Bouttier D, Raymondeaud C, et al. 4 Cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics [in French]. Rev Neurol 1959;100: 751-755
11. Hunter R, Earl CJ, Thornicroft S. An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proc R Soc Med 1964;57:758-762
12. Schönecker M. Ein eigentumliches Syndrom in oralen Bereich bei Megaphenapplikation. Nervenarzt. 1957;28:35-41
13. Kulenkampff VC, Tarnow G. Ein eigentumliches Syndrom im oralen Bereich bei Megaphenapplikation. Nervenarzt 1956;26:178-180
14. Crane GE, Paulson G, Involuntary movements in a sample of chronic mental patients and their relation to the treatment with neuroleptics. Int J Neuropsychiatry 1967;3:286-291
15. Crane GE. Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. Am J Psychiatry 1968;124(Suppl):40-48
16. Talbott JH. Irreversible side effects of phenothiazines. [editorial], JAMA 1965;191:333-334
17. Kline NS. On the rarity of "irreversible" oral dyskinesia following phenothiazines. Am J Psychiatry 1968;124(Suppl):48-54
18. National Institute of Mental Health. Psychotropic drugs and dysfunctions of the basal ganglia. Oct 31-Nov 2, 1968; Workshop Series of Pharmacology Section, NIMH #3. Public health publication 1938:26
19. Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978;135:1321-1324
20. Crane GE. Clinical psychopharmacology in its 20th year. Science 1973;181:124-128
21. Asnis GM, Leopold MA, Duvoisin RC, et al. A survey of tardive dyskinesia in psychiatric outpatients. Am J Psychiatry 1977;134:1367-1370
22. Crane G, Smith RC. The prevalence of tardive dyskinesia. In: Fann WE, Smith RC, Davis JM, et al, eds. Tardive Dyskinesia. New York, NY: Medical and Scientific Books; 1980:269-280
23. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry 1981;138:297-309
24. Gardos G, Samu I, Kallos M, et al. Absence of severe tardive dyskinesia in Hungarian outpatients. Psychopharmacology (Berl) 1980;71:29-34
25. Goetz CG. Diagnosis of tardive dyskinesia. Clin Neuropharmacol 1983; 6:101-107
26. Paulson GW. Tardive dyskinesia. Annu Rev Med 1975;26:75-81
27. Gershanik OS. Drug-induced dyskinesias. In: Jankovic J, Tolsa E, eds. Parkinson's Disease and Movement Disorders. 3rd ed. Baltimore. Md: Williams & Wilkins; 1998:579-599
28. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenics. J Clin Psychiatry 2000;61(suppl 4): 10-14
29. Altrochi PH. Spontaneous oral-facial dyskinesia. Arch Neurol 1972;26: 506-512
30. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ 1985;291:930-932
31. Miller LG, Jankovic J. Metoclopramide-induced movement disorders: clinical findings with a review of the literature. Arch Intern Med 1989; 149:2486-2492
32. Burke RE, Kang UJ, Fahn S. Tardive akathisia: motor phenomena and treatment. Neurology 1987;37(suppl):124-125
33. Christian CD, Paulson GW. Severe motility disturbance after small doses of prochlorperazine. N Engl J Med 1958;259:828-830
34. Kiriakakis V, Bhatia KP, Quinn NP, et al. The natural history of tardive dystonia. Brain 1998;121:2053-2066
35. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late onset and persistent dystonia caused by anti-psychotic drugs. Neurology 1982; 32:1335-1346
36. von Harten PN, Kahn RS. Tardive dystonia. Schizophr Bull 1999; 25:741-748
37. Ghaemi SN. Ko JY Quetiapine-related tardive dyskinesia [letter]. Am J Psychiatry 2001;158:1737
38. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-481
39. Edwards H. The significance of brain damage in persistent oral dyskinesia. Br J Psychiatry 1970;116:271-275
40. Nasrallah HA, Churchill RM, Handan-Allen GA. Higher frequency of neuroleptic induced dystonia in mania than in schizophrenia. Am J Psychiatry 1988;145:1455-1456
41. Klawans HL, Bergen D, Bruger GW, et al. Neuroleptic-induced tardive dyskinesias in nonpsychotic patients. Arch Neurol 1974;30:338-339
42. van Os, Walsh E, van Horn E, et al. Tardive dyskinesia in psychosis: are women more at risk? Acta Psychiatr Scand 1999;99:288-293
43. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry 2000; 61(suppl 4):27-32
44. Paulson GW, Rizvi CA, Crane GE. Tardive dyskinesia as a possible sequel of long term therapy with phenothiazines. Clin Pediatr (Phila) 1975;14:953-955
45. Borison RL, Diamond BI. Anticholinergics promote neuroleptic-induced TD. Adv Biochem Psychopharmacol 1980;17:359-362
46. Jellinck T, Gardos G. Cole J. Adverse effects of anticholinergic drug withdrawal. Am J Psychiatry 1981;138:1567-1571
47. Tanner CM. Drug induced movement disorders. In: Vinken PJ, Bruyn G, Klawans H, eds. Handbook of Clinical Neurology, vol 49: Extrapyramidal Disorders. Amsterdam, the Netherlands: Elsevier; 1986;185-204
48. Klawans HL, Tanner CM, Goetz CG. Epidemiology and pathophysiology of tardive dyskinesia. Adv Neurol 1988;49:185-197
49. Hunter R, Blackwood W, Smith MC, et al. Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication. J Neurol Sci 1968;7:263-273
50. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000;61(suppl 4):5-9
51. Gerratt BR, Goetz CG, Fisher HB. Speech abnormalities in tardive dyskinesia. Arch Neurol 1984;41:273-276
52. Casey DE. Rabins P. Tardive dyskinesias as a life-threatening illness. Am J Psychiatry 1978;135:486-488
53. Klawans H. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med 1978;88:327-331
54. Paulson GW. "Permanent" or complex dyskinesia in the aged. Geriatrics 1968;28:105-110
55. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004;65(suppl 9):16-20
56. Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994;151:836-841
57. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14 year follow-up. Neurology 2001;56:805-807
58. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57:167-173
59. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-1281
60. McGrath JJ, Soares KV. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Sys Rev 2000;2:CD000459
61. Millier CE, Wiles CM, Simpson BA. Thalamotomy for severe antipsychotic induced tardive dyskinesia and dystonia. J Neurol Neurosurg Psychiatry 1999;66:250-251
62. Rapaport A, Sadeh M, Stein D, et al. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord 2000; 15:352-355
63. Slovenko R. Update on legal issues associated with tardive dyskinesia. J Clin Psychiatry 2000;61(suppl 4):45-57
64. Wettstein RM. Tardive dyskinesia and malpractice. Behav Sci Law 1983;1:85-107